Navigation Links
Lead Plaintiff's Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is 'Tip of the Iceberg' of Future Off-Label Marketing Lawsuits
Date:9/17/2010

SHORT HILLS, N.J., Sept. 17 /PRNewswire/ -- Fresh off his victory for a whistle-blower in the Forest Pharmaceuticals, Inc. lawsuit, attorney David Stone is setting his sights on the billions of dollars of settlements he expects awarded in future legal actions involving off-labeling marketing practices.

"The award of $313 million in the Forest Pharmaceuticals case is just the tip of the iceberg in comparison to the amount of off-label marketing kick-back settlements we'll see in the future," Stone said. "Pharmaceutical companies are under increasing competitive pressures. Unfortunately, in their attempts to increase product sales, many are engaging in deceptive and illegal conduct, which has endangered patients' health and even their lives, as well as cost taxpayers billions of healthcare dollars."

Stone, managing partner of Short Hills, NJ-based law firm Stone & Magnanini LLP, represented a physician who originally brought Forest Pharmaceuticals' illegal marketing practices to the government's attention in a 2001 False Claims Act lawsuit. Stone previously served as head of the False Claims Act department for renowned litigator, David Boies, and headed that firm's New Jersey office.

Stone explained that the Federal government is focusing more broadly on pharmaceutical industry marketing practices. The Department of Justice and the Office of the Inspector General are scrutinizing practices tied to relations between drug makers and the physicians who endorse their products; the content and distribution of product promotional materials; and the complex inter-relationship of manufacturers, physicians, insurers and others in the drug-delivery chain.

Forest Pharmaceuticals recently agreed to settle civil and criminal claims based on off-label marketing and kick-backs to physicians for the antidepressant drugs Celexa and Lexapro, and Levothoid, a drug used to treat hypothyroidism, for more than $313 million.  

Stone & Magnanini LLP specializes in False Claims Act cases in the pharmaceutical fraud area – initiating legal actions on behalf of individuals, as well as for third-party payers such as insurance companies and HMOs. The firm also works with pharmaceutical companies to review their existing practices and procedures in light of current DOJ and OIG policy-related initiatives. Visit www.StoneMagnaLaw.com.

Contact:  Mark Clemente, Steinreich Communications, 201-498-1600, mclemente@scompr.com


'/>"/>
SOURCE Stone & Magnanini LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Plaintiffs and Novartis Pharmaceuticals Corporation, a US Subsidiary of Novartis AG, Agree to Resolve All Gender Discrimination Claims Associated With Class Action
2. Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured
3. Remarks as Prepared for Delivery By Attorney General Eric Holder at the AstraZeneca Settlement Announcement
4. Relators Attorneys Comment On AtriCure/DOJ Proposed Settlement
5. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
6. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
9. NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood
10. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
11. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
(Date:7/12/2017)... 2017 CarpalAID is a revolutionary new product that relieves ... Carpal tunnel syndrome affects more than 8 million people a ... of men. The common methods of treating CTS are painful surgery, ... braces or gloves. ... CarpalAID is a clear patch worn on the palm ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... ... ChenMed , a leading provider of value-based care for seniors, today announced ... Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine at the ... for the UVA Health System, brings 30 years of highly relevant experience to his ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced ... its existing adherence automation lines. The ATP® Mini and InspectRx® Mini ... TCG’s standard products, but at a size and price point that can help ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch ... of - living - adjustment (COLA) is a bad deal for older and disabled ... price index (CPI) would grow even more slowly than the conventional one that is ...
Breaking Medicine News(10 mins):